| Jaeyoon Chung, MD | |
|
701 E Marshall St # 141, West Chester, PA 19380-4412 | |
| (610) 431-5472 | |
| Not Available |
| Full Name | Jaeyoon Chung |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 11 Years |
| Location | 701 E Marshall St # 141, West Chester, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508209644 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD474172 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chester County Hospital | West chester, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Clinical Care Associates Of The University Of Pennsylvania Health | 4688588866 | 517 |
News Archive
MicroStockProfit.com announces an investment report featuring Somanetics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported.
Catylix, Inc. and the University of Illinois at Urbana-Champaign have entered into a license agreement under which Catylix will utilize a technology developed by Illinois' Professor John Hartwig to quickly and efficiently introduce fluorine and fluorine-containing substituents into molecules.
Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
› Verified 6 days ago
| Entity Name | Clinical Care Associates Of The University Of Pennsylvania Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972682995 PECOS PAC ID: 4688588866 Enrollment ID: O20031113000301 |
News Archive
MicroStockProfit.com announces an investment report featuring Somanetics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported.
Catylix, Inc. and the University of Illinois at Urbana-Champaign have entered into a license agreement under which Catylix will utilize a technology developed by Illinois' Professor John Hartwig to quickly and efficiently introduce fluorine and fluorine-containing substituents into molecules.
Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jaeyoon Chung, MD 701 E Marshall St # 141, West Chester, PA 19380-4412 Ph: (610) 431-5472 | Jaeyoon Chung, MD 701 E Marshall St # 141, West Chester, PA 19380-4412 Ph: (610) 431-5472 |
News Archive
MicroStockProfit.com announces an investment report featuring Somanetics Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported.
Catylix, Inc. and the University of Illinois at Urbana-Champaign have entered into a license agreement under which Catylix will utilize a technology developed by Illinois' Professor John Hartwig to quickly and efficiently introduce fluorine and fluorine-containing substituents into molecules.
Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate and is a safe and effective treatment option which has shown long term viral eradication.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
› Verified 6 days ago
Dr. Raymund Castro Santos, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5472 | |
Dr. Glenn Ereso, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5387 | |
Craig M Steiner, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5472 | |
Russell L Levin, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5472 | |
Kirby S Tirk, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall St, West Chester, PA 19380 Phone: 610-431-5472 | |
Michael He, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 701 E Marshall Street, Nrw 141, West Chester, PA 19380 Phone: 610-431-5472 | |
Dr. Lelwellyn Antone Raymundo, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 419 Chrislena Ln, West Chester, PA 19380 Phone: 610-738-7680 |